Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
engineered bacterial strain
|
| gptkbp:clinicalTrialPhase |
Phase 1
|
| gptkbp:developedBy |
gptkb:Synlogic,_Inc.
|
| gptkbp:engineeredFor |
treatment of enteric hyperoxaluria
|
| https://www.w3.org/2000/01/rdf-schema#label |
SYNB8802
|
| gptkbp:mechanismOfAction |
degrades oxalate in the gut
|
| gptkbp:organism |
gptkb:Escherichia_coli_Nissle_1917
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:target |
gptkb:secondary_hyperoxaluria
gptkb:primary_hyperoxaluria |
| gptkbp:bfsParent |
gptkb:Synlogic,_Inc.
|
| gptkbp:bfsLayer |
8
|